Humanistic Care in Patients With Coronavirus Disease 2019

Status Withdrawn

Clinical Trial Summary

Clinical Trial Description

As of February 17th, 2020, China has 76396 confirmed cases of coronavirus disease 2019 (COVID-19), including 2348 deaths. Although the impact factors of clinical outcomes among hospitalized patients still need to be clarified, some of the therapeutic regimens have shown their potency in the treatment of severe cases. Investigators aim to evaluate the efficacy of psychological and physical rehabilitation based humanistic care in the treatment of COVID-2019. As the national medical team sent to Wuhan, investigators proposed a Psychological and physical rehabilitation based humanistic care regimen generated from our experience in treating patients with COVID-2019. In addition to routine therapy, investigators will apply this comprehensive humanistic care regimen to the patients according to their condition to see the efficacy to this regimen. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04283825
Study type	Interventional
Source	Second Affiliated Hospital of Xi'an Jiaotong University
Contact
Status	Withdrawn
Phase	N/A
Start date	February 22, 2020
Completion date	May 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05091411` - Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)	Phase 3
Completed	`NCT05107375` - Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine	Phase 3
Active, not recruiting	`NCT05128643` - Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)	Phase 3
Completed	`NCT04988217` - Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)	Phase 1/Phase 2
Completed	`NCT04579393` - Fostamatinib for Hospitalized Adults With COVID-19	Phase 2
Withdrawn	`NCT04390217` - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia	Phase 2
Recruiting	`NCT05047783` - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19	Phase 2
Completed	`NCT04646044` - A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19	Phase 1
Not yet recruiting	`NCT06392451` - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia	N/A
Recruiting	`NCT05092568` - Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
Completed	`NCT05364268` - Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
Completed	`NCT06189040` - Immunogenicity After COVID-19 Vaccines in Adapted Schedules	Phase 4
Recruiting	`NCT04401436` - COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Not yet recruiting	`NCT04395742` - 1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
Recruiting	`NCT04388631` - Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
Completed	`NCT05501288` - Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019	N/A
Active, not recruiting	`NCT05216471` - Identify Coronavirus Disease by Chest X-ray
Terminated	`NCT04672564` - Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients	Phase 3
Completed	`NCT04967781` - Autoimmunity Contributes to the Severe Progression of COVID-19
Completed	`NCT04678830` - Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19	Phase 2